Literature DB >> 6813478

Oral gold therapy with auranofin (SK&F 39162). A multicenter open study in patients with rheumatoid arthritis.

K Bandilla, D Gross, W Gross, J D Herrlinger, W Kriegel, W Müller, W Siegmeth, G Tausch, N Thumb, F J Wagenhäuser.   

Abstract

One hundred and fifty patients with rheumatoid arthritis received 6 mg of auranofin daily for 2-24 months. Thirty patients were withdrawn from the study, and 82 patients were observed for 12 months. Statistical evaluation was available for 74 patients at weeks 24, 38, and 48, respectively. The major side effects observed were diarrhea, rash, and alopecia. Significant improvement was noted in the articular index, ESR, pain, and morning stiffness.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6813478

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN： 0380-0903


  7 in total

1.  Investigation of auranofin-induced diarrhoea.

Authors:  R Behrens; M Devereaux; B Hazleman; K Szaz; J Calvin; G Neale
Journal:  Gut       Date:  1986-01       Impact factor: 23.059

Review 2.  Current status of disease-modifying drugs in progressive rheumatoid arthritis.

Authors:  J D O'Duffy; H S Luthra
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

3.  Effects of auranofin and myochrysine on intestinal transport and morphology in the rat.

Authors:  H V Ammon; S A Fowle; J A Cunningham; R A Komorowski; R F Loeffler
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

Review 4.  Gold colitis induced by auranofin treatment of rheumatoid arthritis: case report and review of the literature.

Authors:  H E Langer; G Hartmann; G Heinemann; K Richter
Journal:  Ann Rheum Dis       Date:  1987-10       Impact factor: 19.103

Review 5.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

6.  Auranofin in juvenile rheumatoid arthritis. An open label, non-controlled study.

Authors:  O Garcia-Morteo; M E Suarez-Almazor; J A Maldonado-Cocco; R Cuttica; S Abate
Journal:  Clin Rheumatol       Date:  1984-06       Impact factor: 2.980

7.  Auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Cooperative systematic studies of rheumatic diseases.

Authors:  H J Williams; J R Ward; M J Egger; J C Reading; C O Samuelson; M Altz-Smith; R W Willkens; M A Solsky; S P Hayes; D Furst
Journal:  Clin Rheumatol       Date:  1984-03       Impact factor: 2.980
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.